neurology
Clinically Isolated Syndrome (CIS) Risk of MS
Estimates risk of conversion from clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (CDMS) based on MRI and clinical features.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Dimethyl Fumarate · Disease-Modifying Therapy — Relapsing-Remitting Multiple Sclerosis
- Ocrelizumab · Multiple Sclerosis — Disease-Modifying Therapy
- Fingolimod · Multiple Sclerosis — Disease-Modifying Therapy
- Alemtuzumab · Multiple Sclerosis — Disease-Modifying Therapy
- Cladribine · Multiple Sclerosis — Disease-Modifying Therapy
- Ofatumumab · Multiple Sclerosis — Disease-Modifying Therapy
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.